NTNU and St. Olavs hospital
The MR Cancer Group at NTNU has focused on research, development and implementation of MR methods for cancer diagnosis and treatment monitoring since 1990, when it was established by Prof. Ingrid Gribbestad. The long‐term objective of the MR Cancer Group is to improve and individualize cancer treatment by developing integrated MR methods and data analysis tools for functional and molecular tumour characterization. Although clinical research has high priority, a broad spectrum of systems for cancer studies provides translational research, covering ex vivo as well as in vivo MR imaging and spectroscopy of cancer cells and laboratory animals. Current research activities focus on the use of advanced MRI and in vivo MRS in diagnosis and therapy monitoring, in addition to the development of ex vivo HR MAS MR spectroscopy for metabolomic classification of intact cancer specimens and biofluids (MR metabolomics).
The AI group in Trondheim is led by Marit Valla, associate professor at NTNU and consultant in pathology at St. Olav’s hospital. The project is a collaboration between NTNU, St. Olavs Hospital and SINTEF. By combining knowledge of pathology, clinical medicine and artificial intelligence (artificial intelligence, AI) we want to develop an AI-based platform that can be used to segment various tissue components into digital tissue sections from breast cancer tumors, and to predict biological properties and prognosis in these tumors.
- A Simplified Approach to Measure the Effect of the Microvasculature in Diffusion-weighted MR Imaging Applied to Breast Tumors: Preliminary Results.
- Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes.
- Impact of Freezing Delay Time on Tissue Samples for Metabolomic Studies.
- Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.